Cargando…

Identification of genes and cellular response factors related to immunotherapy response in mismatch repair-proficient colorectal cancer: a bioinformatics analysis

BACKGROUND: Mismatch repair-proficient (pMMR) colorectal cancers (CRCs) are thought to be primarily resistant to immune checkpoint inhibitor (ICI) monotherapy. However, recent clinical trials have reported that early-to-mid stage (non-metastatic) CRC responds well to ICI monotherapy. We hypothesized...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xue, Wenxiu, Shi, Jinglong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830321/ https://www.ncbi.nlm.nih.gov/pubmed/36636048 http://dx.doi.org/10.21037/jgo-22-1070

Ejemplares similares

Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2023)

Robust Glycogene-Based Prognostic Signature for Proficient Mismatch Repair Colorectal Adenocarcinoma
por: Li, Yixi, et al.
Publicado: (2021)

Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer
por: Zhou, Guoying, et al.
Publicado: (2018)

Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
por: Meltzer, Sebastian, et al.
Publicado: (2022)

Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer
por: He, Yinjun, et al.
Publicado: (2023)

Immunoscore in mismatch repair‐proficient and ‐deficient colon cancer
por: Wirta, Erkki‐Ville, et al.
Publicado: (2017)

Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer
por: Eppenberger, Manuela, et al.
Publicado: (2010)

Characterisation of the oxysterol metabolising enzyme pathway in mismatch repair proficient and deficient colorectal cancer
por: Swan, Rebecca, et al.
Publicado: (2016)

Immuno-Contexture and Immune Checkpoint Molecule Expression in Mismatch Repair Proficient Colorectal Carcinoma
por: Giacomelli, Mauro, et al.
Publicado: (2023)

Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients
por: Liu, Shou-Sheng, et al.
Publicado: (2018)

Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers
por: Hale, Vanessa L., et al.
Publicado: (2018)

IGSF6 is a novel biomarker to evaluate immune infiltration in mismatch repair-proficient colorectal cancer
por: Rong, Yu-ming, et al.
Publicado: (2023)

Photodynamic therapy of DNA mismatch repair-deficient and -proficient tumour cells
por: Schwarz, V A, et al.
Publicado: (2002)

Gut microbiota distinct between colorectal cancers with deficient and proficient mismatch repair: A study of 230 CRC patients
por: Jin, Min, et al.
Publicado: (2022)

Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort
por: Zwart, Koen, et al.
Publicado: (2023)

Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer
por: Jimenez-Rodriguez, Rosa M., et al.
Publicado: (2020)

Risk for Hereditary Neoplastic Syndromes in Women with Mismatch Repair-Proficient Endometrial Cancer
por: dos Santos, Jennifer Thalita Targino, et al.
Publicado: (2023)

Identification and analysis of biomarkers for mismatch repair proteins: A bioinformatic approach
por: Sehgal, Manika, et al.
Publicado: (2012)

Dendritic cell paucity in mismatch repair–proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy
por: Ho, William W., et al.
Publicado: (2021)

Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era?
por: Matteucci, Laura, et al.
Publicado: (2023)

Imaging Mismatch Repair and Cellular Responses to DNA Damage in Bacillus subtilis
por: Klocko, Andrew D., et al.
Publicado: (2010)

ASO Author Reflections: Clinical Outcome After Upfront Curative-Intent Local Treatment of Metastases in Patient with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer
por: Zwart, Koen, et al.
Publicado: (2023)

Combined Antiangiogenic Therapy and Immunotherapy Is Effective for Pancreatic Cancer With Mismatch Repair Proficiency but High Tumor Mutation Burden: A Case Report
por: Chen, Mengni, et al.
Publicado: (2019)

Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2022)

DNA mismatch repair in cancer immunotherapy
por: Guan, Junhong, et al.
Publicado: (2023)

Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer
por: Liu, Shousheng, et al.
Publicado: (2019)

A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer
por: Yarchoan, Mark, et al.
Publicado: (2019)

Immune microenvironment in patients with mismatch‐repair‐proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study
por: Jary, Marine, et al.
Publicado: (2022)

Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells
por: Nehmé, A, et al.
Publicado: (1999)

Efficient engineering of chromosomal ribosome binding site libraries in mismatch repair proficient Escherichia coli
por: Oesterle, Sabine, et al.
Publicado: (2017)

Immunohistochemical mismatch repair proteins expression as a tool to predict the melanoma immunotherapy response
por: Ponti, Giovanni, et al.
Publicado: (2020)

Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers
por: Li, Jinming, et al.
Publicado: (2023)

Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era
por: Wensink, G. Emerens, et al.
Publicado: (2020)

Aspirin-induced nuclear translocation of NFκB and apoptosis in colorectal cancer is independent of p53 status and DNA mismatch repair proficiency
por: Din, F V N, et al.
Publicado: (2005)

TIA-1 Cytotoxic Granule-Associated RNA Binding Protein Improves the Prognostic Performance of CD8 in Mismatch Repair-Proficient Colorectal Cancer
por: Zlobec, Inti, et al.
Publicado: (2010)

Immune Checkpoint Inhibitors in Mismatch Repair Proficient/Microsatellite Stable Metastatic Colorectal Cancer Patients: Insights from the AtezoTRIBE and MAYA Trials
por: Germani, Marco Maria, et al.
Publicado: (2021)

BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
por: Fu, Yu, et al.
Publicado: (2023)

The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers
por: Wang, Qiao-Xuan, et al.
Publicado: (2021)

Dynamics of genomic and immune responses during primary immunotherapy resistance in mismatch repair–deficient tumors
por: Takahashi, Nobuyuki, et al.
Publicado: (2020)

Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair‐Deficient Prostate Cancer
por: Sena, Laura A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9euqg7fspjerl6d1dhuof939b2